Skip to main content
LTRN
NASDAQ Life Sciences

Lantern Pharma Q3: $7.6M Cash, Going-Concern Warning, Interim CEO After Sharma Exit

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.372
Mkt Cap
$5.451M
52W Low
$0.362
52W High
$4.34
52W Position info
2.9% above low
Off High info
91% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

LTRN is trading near its 52-week low of $0.362 (2.9% above the low) on light trading volume (0.4× avg).

Summary

Lantern ended Q3 with about $7.6 million in cash and marketable securities, down from $10.1 million at year-end 2025, and states plainly that this is not enough to fund operations for the next 12 months — substantial doubt about going concern. The reported $0.7 million net income ($0.05 per basic share) is an accounting artifact: a $6.0 million non-cash gain from remeasuring the May 2026 warrants, not operating improvement. Strip out the $2.0 million accrual for the proposed harassment/discrimination settlement and the operating loss was $3.4 million, down 22% year over year as R&D fell 36% to $1.6 million — the company is shrinking trial spend to conserve cash. Leadership is in flux: Panna Sharma resigned as President, CEO and director effective November 15, with CFO David Margrave interim CEO while the board searches for a permanent replacement. This comes on top of the October 1 Nasdaq delisting notice for failing the $35 million minimum market value test and a second deficiency for the sub-$1.00 bid, with the stock at $0.37 near its 52-week low. The $2.0 million settlement is only half payable in 30 days; the second $1.0 million is contingent on raising at least $10.0 million in gross proceeds, so the company needs a large capital raise to satisfy it. The pipeline updates (Taiwan IRB approval for HARMONIC Part 2, the LP-184 glioblastoma publication, the LP-284 patent allowance) are incremental and already disclosed; the planned LP-184 plus spironolactone Phase 1b/2a trial is explicitly subject to obtaining additional funding.

At the time of this announcement, LTRN was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.36 to $4.34. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

LTRN - Latest Insights

LTRN
Nov 18, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3724
Real-time Price: $0.3695 info
Change: -$0.0029 (-0.78%) info
Market Cap: $5.451M info
LTRN
Nov 17, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.3695 info
Change: +$0.0045 (+1%) info
Market Cap: $5.451M info
LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.3695 info
Change: -$0.4605 (-55%) info
Market Cap: $5.451M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.3695 info
Change: -$0.5805 (-61%) info
Market Cap: $5.451M info
LTRN
Oct 01, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.00
Real-time Price: $0.3695 info
Change: -$0.6305 (-63%) info
Market Cap: $5.451M info